The Pearl Group said at the performance briefing that the company continues to focus on the development of innovative drugs, complex formulations with high barriers and high clinical value products to drive performance growth through innovation. It is expected that aripiprazole microspheres and simeglutide in the neuropsychiatric and metabolic fields will be approved for marketing within this year. Simeglutide has two indications under study. Among them, the indication for type 2 diabetes is under marketing review and is expected to be approved for marketing by the end of this year or the beginning of next year; the phase III clinical trial for weight loss indications has been completed, and a marketing application is expected to be submitted by the end of 2025.

The Pearl Group said at the performance briefing that the company continues to focus on the development of innovative drugs, complex formulations with high barriers and high clinical value products to drive performance growth through innovation. It is expected that aripiprazole microspheres and simeglutide in the neuropsychiatric and metabolic fields will be approved for marketing within this year. Simeglutide has two indications under study. Among them, the indication for type 2 diabetes is under marketing review and is expected to be approved for marketing by the end of this year or the beginning of next year; the phase III clinical trial for weight loss indications has been completed, and a marketing application is expected to be submitted by the end of 2025.